IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology firm in Mountain View, California, focuses on engineered IgM antibodies. On May 12, 2020, the company announced that CEO Fred Schwarzer will present at the 2020 RBC Capital Markets Global Healthcare Conference on May 19 at 4:15 p.m. ET. The event will be virtual, and a live webcast can be accessed from the Company’s website, with a replay available for 90 days after the event.

IGM Biosciences has developed a proprietary IgM technology platform, aimed at enhancing the therapeutic applications of IgM antibodies.

News Market Reaction – IGMS

-8.33%

-8.33% Session move

In the trading session that priced this news, IGMS declined 8.33%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MOUNTAIN VIEW, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 4:15 p.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com

FAQ

When will IGM Biosciences present at the RBC Capital Markets Global Healthcare Conference?

IGM Biosciences will present on May 19, 2020, at 4:15 p.m. ET.

Where can I watch the IGM Biosciences conference presentation?

The presentation will be available via a live webcast on the 'Events and Presentations' page of IGM Biosciences' website.

How long will the IGM Biosciences conference replay be available?

The replay of the presentation will be archived for 90 days following the event.

What is the focus of IGM Biosciences?

IGM Biosciences specializes in creating and developing engineered IgM antibodies.

Where is IGM Biosciences headquartered?

IGM Biosciences is headquartered in Mountain View, California.